Incremental direct healthcare expenditures of valvular heart disease in the USA

J Comp Eff Res. 2019 Aug;8(11):879-887. doi: 10.2217/cer-2019-0007. Epub 2019 Aug 21.


Aim: To quantify the healthcare expenditures for valvular heart disease (VHD) in the USA. Patients & methods: Direct annual incremental healthcare expenditures were estimated using multiple logistic and linear regression models. Results were stratified by age cohorts (18-64 years, ≥65 and ≥75 years) and disease status: symptomatic aortic valve disease (AVD), asymptomatic AVD, symptomatic mitral valve disease (MVD) and asymptomatic MVD. Results: A total of 1463 VHD patients were identified. The overall aggregated incremental direct expenditures were $56.62 billion ($26.48 billion for patients ≥75 years). Individuals ≥75 years with symptomatic AVD had the largest incremental effect on annual, per-patient healthcare expenditure of $30,949. The annualized incremental costs of VHD were greatest for individuals ≥75 years with AVD. Conclusion: Identification of VHD at an earlier stage may reduce the economic burden.

Keywords: health economics; healthcare costs; medical expenditures; valvular heart disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Age Factors
  • Aged
  • Costs and Cost Analysis
  • Female
  • Health Expenditures / statistics & numerical data*
  • Heart Valve Diseases / economics*
  • Humans
  • Male
  • Middle Aged
  • United States / epidemiology
  • Young Adult